Search the Newsreel

The Technical Signals Behind (NCNO) That Institutions Follow

This article provides a technical analysis of Ncino Inc. (NASDAQ: NCNO), highlighting mixed sentiment and no clear price positioning signal. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. …

National CineMedia To Acquire Captivate For $275M, Expands From Movie Theater Ads To Offices & Apartment Buildings

National CineMedia is set to acquire Captivate Holdings for $275 million, expanding its advertising reach from movie theaters to digital video screens in office and residential buildings. This acquisition will create a major player in premium video and digital out-of-home advertising with over 48,000 …

National CineMedia (NCMI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

National CineMedia earnings missed by $0.07, revenue fell short of estimates

Earnings call transcript: National CineMedia misses Q2 2026 estimates, shares drop

National CineMedia (NCMI) reported Q2 2026 revenue and earnings below analyst estimates, leading to a 15.57% drop in after-hours trading. Despite a 12.7% revenue increase year-over-year and improved operating profit, the company posted a wider loss than expected. Management paused forward guidance due to …

Generation Partners announces sale of Captivate Network to National CineMedia (NASDAQ: NCMI)

Generation Partners announced the sale of its majority ownership in Captivate Holdings LLC to National CineMedia, Inc. Captivate, a leading operator of digital video elevator and lobby advertising in North America, was acquired by Generation Partners in 2013 and transformed into an industry leader …

National CineMedia (NCMI) lifts cash flow, plans $275M Captivate deal

National CineMedia (NCMI) Reports Q2 Loss, Lags Revenue Estimates

National CineMedia (NCMI) Stock Rises on Q2 2026 Earnings

National CineMedia (NCMI) reported second-quarter 2026 revenue of $58.4 million, a 12.7% increase year-over-year, despite a net loss of $9.9 million. Following the earnings release, the company's shares rose 8.0% after market close, reflecting improved liquidity and operating cash flow. The article also details …

National CineMedia, Inc. Q2 2026: Revenue $58.4M, EPS $(0.11) — 10-Q Summary

National CineMedia, Inc. (NCMI) reported Q2 2026 results, showing revenue increased to $58.4 million, up 12.7% year-over-year. The company's net loss narrowed to $(9.9) million, though diluted EPS remained unchanged at $(0.11). Growth was driven by higher national and local ad sales, expanded theater …

Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?

Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia. On August 10, the company announced a multi-part collaboration with BeOne Medicines, pairing clinical development with a regional rights deal. For a stock that has already climbed more …

Cintas Corp. stock underperforms Tuesday when compared to competitors despite daily gains

Cintas Corp. (CTAS) stock gained 1.27% on Tuesday, closing at $205.28, despite a broader market downturn. However, the stock underperformed its competitors, and remains 9.44% below its 52-week high.

National CineMedia (NASDAQ:NCMI) Releases Earnings Results, Misses Expectations By $0.02 EPS

National CineMedia: Q2 Earnings Snapshot

This article is a Q2 earnings snapshot for National CineMedia. However, the provided content is empty beyond a privacy message and image links, indicating that the actual earnings data is missing.

National CineMedia Plans $275M Deal for More Than 48,000 Screens

Q2 2026 Cineplex Inc Earnings Call Transcript

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

BeOne Medicines and Revolution Medicines have announced a multi-part collaboration to evaluate drug combinations for RAS-addicted cancers and extend the geographic footprint of Revolution Medicines' therapies. The deal includes a clinical collaboration for combination studies using BeOne's oncology assets and Revolution's four RAS(ON) inhibitors, …

Cingulate's Once-Daily ADHD Candidate Shows Higher Later-Day Levels

Cingulate Inc. (NASDAQ: CING) announced the publication of peer-reviewed data in CNS Drugs detailing the pharmacokinetic profile of its lead ADHD product candidate, CTx-1301. The study demonstrated that CTx-1301 provides rapid initial dexmethylphenidate exposure comparable to existing treatments, but crucially maintains statistically higher plasma …

Equities Analysts Offer Predictions for PRAX Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Praxis Precision Medicines (NASDAQ:PRAX) to a loss of $3.86 per share, maintaining a "Buy" rating and a $1,201 price target, indicating expectations for profitability by Q4 2027. Several other analysts also weighed in on …

Earnings Flash (CGX.TO) Cineplex Inc. Reports Q2 Revenue C$383.7M, vs. FactSet Est of C$378.7M

KMG Fiduciary Partners LLC Reduces Stake in Cintas Corporation $CTAS

KMG Fiduciary Partners LLC significantly reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 65.6% in the second quarter, selling 16,995 shares and retaining 8,923 shares worth $1.52 million. Despite this, Cintas reported strong quarterly earnings, beating expectations with $1.29 EPS and $2.91 billion in …

InSilico Medicine Sets Board Meeting to Approve Interim Results and Dividend

Cingulate (CING) Expected to Announce Earnings on Tuesday

Cingulate (CING) is projected to report its Q2 2026 earnings before market open on Tuesday, August 18th, with analysts forecasting a loss of $0.63 per share and revenue of $167,000. The company previously missed Q1 2026 consensus estimates with a loss of $0.95 per …

H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201

H.C. Wainwright has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US), maintaining a target price of $1,201. This indicates continued confidence from the firm in the company's future performance.

Renaissance Technologies LLC Sells 31,000 Shares of Disc Medicine, Inc. $IRON

Renaissance Technologies LLC reduced its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 49.3% in the first quarter, selling 31,000 shares and retaining 31,820 shares worth approximately $2.035 million. Despite this sale, other institutional investors increased their holdings, and company insiders sold over 110,000 shares …

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Cingulate Inc. announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in CNS Drugs, showcasing the differentiated pharmacokinetic profile of its lead ADHD product candidate, CTx-1301. The study supports Cingulate’s Precision Timed Release™ (PTR™) platform, demonstrating rapid onset and extended medication …

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?

Weekly Recap: Q2 revenue drop and Brilzio partner search

Lipocine Inc (NASDAQ:LPCN) reported a Q2 2026 adjusted loss of $0.32 per share and a significant 69.5% drop in revenue to $190,099, resulting in a net loss of $2.62 million. The company is actively seeking partners for its postpartum depression drug, Brilzio, and is …

Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD

Bank of America Corp DE reduced its stake in Revolution Medicines, Inc. by 30.2% in Q1 2026, selling 265,688 shares and retaining 614,157 shares valued at $59.7 million. Despite this, institutional investors own 94.34% of the company, and Wall Street analysts generally maintain a …

Projeções de Resultados: Cintas Corp (CTAS) — LPA e Crescimento de Receita

How Investors May Respond To Cincinnati Financial (CINF) Strong Q2 Earnings Beat And Major Buyback Completion

Cincinnati Financial (CINF) reported strong Q2 2026 results with higher revenue and net income, alongside completing a significant share buyback program that reduced its share count by over one-fifth. While these results strengthen the near-term earnings outlook, the company's investment narrative still includes exposure …

National CineMedia (NASDAQ:NCMI) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

National CineMedia's (NASDAQ:NCMI) share price recently rose above its 200-day moving average, reaching $4.02 before settling at $3.95, while the 200-day average is $3.51. Despite exceeding quarterly revenue and narrowing its adjusted loss, the company remains unprofitable and analysts maintain a consensus "Hold" rating …

Why Is Cineverse Stock Rising Despite Missing Q3 Revenue and Earnings Estimates?

Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus

Revolution Medicines (RVMD) recently announced a collaboration with BeOne Medicines, impacting its stock valuation. While analysts set a consensus price target slightly below the current share price at $204.38, Simply Wall St's DCF model suggests a deep undervaluation at $721.01. The article highlights the …

H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8

H.C. Wainwright has reiterated its Buy rating for Prime Medicine (PRME.US) and maintained its target price at $8. This indicates a continued positive outlook from the firm regarding Prime Medicine's stock performance.

Cincinnati Financial Corp. stock underperforms Monday when compared to competitors

Shares of Cincinnati Financial Corp. (CINF) fell by 1.70% on Monday, closing at $173.86. This underperformance occurred during a generally negative trading session, with both the S&P 500 Index and the Dow Jones Industrial Average also experiencing slight declines. This marked the second consecutive …